We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AV-GBM-1

News List

Cancer vaccine shows promise in glioblastoma trial europeanpharmaceuticalreview
June 11, 2021
Personalised cancer vaccine increases progression free survival by approximately 50 percent in patients with newly diagnosed glioblastoma.
AIVITA Biomedical's Glioblastoma Trial Shows Improved Progression Free Survival americanpharmaceuticalreview
December 02, 2020
AIVITA Biomedical announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM).
AIVITA Biomedical Completes Treatment of Patients in Glioblastoma Immunotherapy Trial americanpharmaceuticalreview
November 11, 2020
AIVITA Biomedical announced treatment has been completed for all 57 patients in the Phase 2 clinical trial of AV-GBM-1 in patients with glioblastoma.